Prolonged release tapentadol in the management of chronic cancer pain with strong neuropathic component – report of 2 clinical cases

Marcin Janecki

eISSN: 2081-2833
ISSN: 2081-0016

Medycyna Paliatywna/Palliative Medicine

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

2/2017
vol. 9

Send email

Copy url:

abstract:

Prolonged release tapentadol in the management of chronic cancer pain with strong neuropathic component – report of 2 clinical cases

Marcin Janecki

Medycyna Paliatywna 2017; 9(2): 115–119

Online publish date: 2017/10/30

View full text Get citation

Tapentadol, mu receptor agonist (MOR) and noradrenaline reuptake inhibitor (NRI), is the first drug in novel class of centrally acting analgetics (MOR-NRI). Both mechanisms are considered to contribute synergistically to the analgesic efficacy and reducing typical opioid side effects (especially gastrointestinal symptoms, e.g. constipation, nausea, vomiting or central nervous system disorders). The author presented case reports of two patients with severe nociceptive-neuropathic cancer pain (bone pain and chemotherapy induced pain) treated with tapentadol PR. In both cases tapentadol PR in daily doses up to 200 mg proved to be very efficient and safe, including the combination with morphine CR. The tapentadol treatment remained effective and well-tolerated for several months observation.

keywords:

Prolonged release tapentadol in the management of chronic cancer pain with strong neuropathic component – report of 2 clinical cases

Marcin Janecki

chronic pain, cancer neuropathic pain, tapentadol